Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Evidence is growing that some patients are not responsive to the antithrombotic action of aspirin. We prospectively evaluated the ability of aspirin resistance status, determined by PFA-100, to predict new thrombotic events in patients with stable ischemic cerebrovascular disease. Methods: We studied 129 consecutive patients with stroke, transient ischemic attack (TIA) or vascular cognitive impairment. We assessed relationships between aspirin resistance, risk factors for ischemic cerebrovascular disease, and occurrence of new thrombotic events (composite of stroke, TIA, myocardial infarction, and cardiovascular death). Results: Aspirin resistance, found in 26 (20.1%) cases, was unrelated to any of the examined vascular risk factors. During mean follow-up of 56 months, new thrombotic events occurred in 19 patients (14.7%), four with aspirin resistance (15.4%) and 15 (14.6%) without aspirin resistance (p = 1.00). Conclusion: Aspirin resistance determined by PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease.

Original languageEnglish
Pages (from-to)270-273
Number of pages4
JournalClinical Neurology and Neurosurgery
Volume111
Issue number3
DOIs
Publication statusPublished - Apr 2009

Keywords

  • Aspirin resistance
  • Cerebrovascular disease
  • Ischemic stroke
  • PFA-100
  • TIA

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Fingerprint Dive into the research topics of 'Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease'. Together they form a unique fingerprint.

Cite this